Management of hyperphosphatemia

Hemodialysis International

Volumn 10, Issue 4, 2006, Pages 338-345

  Kuhlmann, Martin K ^a  

^a VIVANTES KLINIKUM IM FRIEDRICHSHAIN   (Germany)

Author keywords

Dialyzer clearance; Diet; Phosphate balancer; Phosphate binder

Indexed keywords

ALUMINUM SALT; BILE ACID SEQUESTRANT; CALCIUM ACETATE; CALCIUM CARBONATE; IRON OXIDE; LANTHANUM CHLORIDE; MAGNESIUM SALT; PHOSPHATE BINDING AGENT; PHOSPHORUS; SEVELAMER;

ARTICLE; CARBOHYDRATE INTAKE; DIALYSATE; DIALYSIS MEMBRANE; DIET RESTRICTION; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; HEMATOCRIT; HEMODIAFILTRATION; HEMODIALYSIS PATIENT; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; KIDNEY FAILURE; PHOSPHATE BLOOD LEVEL; PHYSICAL ACTIVITY; PRESCRIPTION; PREVALENCE; PROTEIN CALORIE MALNUTRITION; RISK FACTOR; TREATMENT DURATION;

BLOOD FLOW VELOCITY; CARDIOVASCULAR DISEASES; EXERTION; HEMATOCRIT; HEMODIAFILTRATION; HUMANS; KIDNEY FAILURE, CHRONIC; KINETICS; MEMBRANES, ARTIFICIAL; PHOSPHATES; PHOSPHORUS, DIETARY; PHYSICAL EXERTION; RENAL DIALYSIS; RISK FACTORS; SURFACE PROPERTIES; TIME FACTORS;

EID: 33749356836     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2006.00126.x     Document Type: Article

References (37)

1. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998; 9: S16-S23.
2. Melamed ML, Eutace JA, Plantinga L, et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: A longitudinal study. Kidney Int. 2006; 70: 351-357.
3. Block GA, Port FK. Re-evaluation of risk associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management. Am J Kidney Dis. 2000; 35: 1226-1237.
4. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension. 2001; 38: 938-942.
5. Slatopolsky E, Brown A, Dusso A. Role of phosphorus in the pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis. 2001; 37 (Suppl 2): S54-S57.
6. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000; 342: 1478-1483.
7. Taylor AJ, Burke AP, O'Malley PG, et al. A comparison of the Framingham risk index, coronary artery calcification, and culprit plaque morphology in sudden cardiac death. Circulation. 2000; 101: 1243-1248.
8. National Kidney Foundation. K/DOQI Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003; 42 (Suppl 3): S1-S202.
9. Levin NW, Gotch FA, Kuhlmann MK. Factors for increased morbidity and mortality in uremia: Hyperphosphatemia. Semin Nephrol. 2004; 24: 396-400.
10. DeSoi CA, Umans JG. Phosphate kinetics during high-flux hemodialysis. J Am Soc Nephrol. 1993; 4: 1214-1218.
11. Gotch FA, Panlilio F, Sergeyeva O, et al. A kinetic model of inorganic phosphorus mass balance in hemodialysis therapy. Blood Purif. 2003; 21: 51-57.
12. Spalding EM, Chamney PW, Farrington K. Phosphate kinetics during hemodialysis: Evidence for biphasic regulation. Kidney Int. 2002; 61: 655-667.
13. Mandolfo S, Malberti F, Imbasciati E, Cogliati P, Gauly A. Impact of blood and dialysate flow and surface on performance of new polysulfone hemodialysis dialyzers. Int J Artif Organs. 2003; 26: 113-120.
14. Gutzwiller JP, Schneditz D, Huber AR, Schindler C, Garbani E, Zehnder CE. Increasing blood flow increases Kt/V(urea) and potassium removal but fails to improve phosphate removal. Clin Nephrol. 2003; 59: 130-136.
15. Gotch FA, Panlilio F, Sergeyeva O, et al. Effective diffusion volume flow rates (Qe) for urea, creatinine, and inorganic phosphorous (Qeu, Qecr, QeiP) during hemodialysis. Semin Dial. 2003; 16: 474-476.
16. Hauk M, Kuhlmann MK, Riegel W, Kohler H. In vivo effects of dialysate flow rate on Kt/V in maintenance hemodialysis patients. Am J Kidney Dis. 2000; 35: 105-111.
17. Vaithilingam I, Polkinghorne KR, Atkins RC, Kerr PG. Time and exercise improve phosphate removal in hemodialysis patients. Am J Kidney Dis. 2004; 43: 85-89.
18. Minutolo R, Bellizzi V, Cioffi M, et al. Postdialytic rebound of serum phosphorus: Pathogenetic and clinical insights. J Am Soc Nephrol. 2002; 13: 1046-1054.
19. Zehnder C, Gutzwiller JP, Renggli K. Hemodiafiltration - a new treatment option for hyperphosphatemia in hemodialysis patients. Clin Nephrol. 1999; 52: 152-159.
20. Lindsay RM, Alhejaili F, Nesrallah G, et al. Calcium and phosphate balance with quotidian hemodialysis. Am J Kidney Dis. 2003; 42 (Suppl 1): 24-29.
21. Pierratos A, Ouwendyk M, Francoeur R, et al. Nocturnal hemodialysis: Three-year experience. J Am Soc Nephrol. 1998; 9: 859-868.
22. Mucsi I, Hercz G, Uldall R, et al. Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int. 1998; 53: 1399-1404.
23. Yuen D, Richardson RM, Chan CT. Improvements in phosphate control with short daily in-center hemodialysis. Clin Nephrol. 2005; 64: 364-370.
24. Ayus JC, Mizani MR, Achinger JG, et al. Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: A prospective controlled study. JASN. 2005; 16: 2778-2788.
25. Maduell F, Navarro V, Torregrosa E, et al. Change from three times a week on-line hemodiafiltration to short daily on-line hemodiafiltration. Kidney Int. 2003; 64: 305-313.
26. Uribarri J, Calvo MS. Hidden sources of phosphorus in the typical American diet: Does it matter in nephrology? Semin Dial. 2003; 16: 186-188.
27. Murphy-Gutekunst L. Hidden phosphorous in popular beverages. J Ren Nutr. 2005; 15: E1-e6.
28. NKF-K/DOQI. Clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis. 2000; 35 (Suppl 2): S1-S140.
29. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002; 62: 245-252.
30. Bleyer AJ, Burke SK, Dillon M, et al. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis. 1999; 33: 694-701.
31. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002; 62: 245-252.
32. Katsumata K, Kusano K, Hirata M. Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats. Kidney Int. 2003; 64: 441-450.
33. Chertow GM, Burke SK, Dillon MA, Slatopolsky A. Long-term effects of sevelamer hydrochloride on the calcium × phosphate product and lipid profile of hemodialysis patients. Nephrol Dial Transplant. 1999; 14: 2907-2914.
34. Braunlin W, Zhorov E, Guo A, et al. Bile acid binding to sevelamer HCl. Kidney Int. 2002; 62: 611-619.
35. Joy MS, Finn WF. Randomized, double blind, placebo-controlled, dose titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: A new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis. 2003; 42: 96-107.
36. Nolan CR, Qunibi W. Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis. Kidney Int. 2005; 67: S13-S20.
37. Bellasi A, Kooienga L., Block G.A. Phosphate binders: New products and challenges. Hemodial Int. 2006; 10: 225-234.